TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT05572983

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating Chidamide combined with CHOP and Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Chidamide combined with CHOP (DRUG): A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po | Chidamide (DRUG): Chidamide: 20mg，qw（d1,d4）,po

Drugs / treatments
Chidamide combined with CHOP, Chidamide
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

NCT05572983

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is evaluating Chidamide combined with CHOP and Chidamide as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 75 Years years
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Chidamide combined with CHOP (DRUG): A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po | Chidamide (DRUG): Chidamide: 20mg，qw（d1,d4）,po

Drugs / treatments: Chidamide combined with CHOP, Chidamide

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 47 patients

Primary endpoint: Complete remission rate

Ages: 18 Years to 75 Years

Start date: 2022-09-01 | Est. completion: 2026-09-01

Locations

0 US sites · 1 total

Contact

Qingqing Cai | caiqq@sysucc.org.cn | 0086-20-87342823

Sponsor: Sun Yat-sen University (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05572983

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.